THE EFFECT OF NISOLDIPINE AS COMPARED WITH ENALAPRIL ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES AND HYPERTENSION
暂无分享,去创建一个
Illiam | Obert | B. L. | Arrett | S. W. | aymond | Effers | J. W | H. R. | E. O | Stacio | Iatt | Tacy | B. L. | Iggerstaff | Chrier | E. O | E. O. | H. R. | S. W | Obert | Aymond | E. O. | Stacio | J. W. | Effers | Illiam | H. R. | Iatt | Tacy | Iggerstaff | Chrier | H. R
[1] M. Rocco,et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. , 1996, JAMA.
[2] H. Parving. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. , 1996, Journal of diabetes and its complications.
[3] I. Amende,et al. Nisoldipine versus isosorbide dinitrate in coronary heart disease: results of a double-masked study. , 1996, Clinical therapeutics.
[4] F. Locatelli,et al. Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .
[5] M. Lishner,et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. , 1996, Archives of internal medicine.
[6] R. Schrier,et al. Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial. , 1996, Controlled clinical trials.
[7] E. Lewis. Angiotensin-converting enzyme inhibition in type I diabetic nephropathy. , 1996, Contributions to nephrology.
[8] B. Psaty,et al. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.
[9] T. Raghunathan,et al. The risk of myocardial infarction associated with antihypertensive drug therapies. , 1995, JAMA.
[10] K. Nademanee,et al. Antianginal and Antiischemic Efficacy of Monotherapy Extended‐Release Nisoldipine (Coat Core) in Chronic Stable Angina , 1995, Journal of clinical pharmacology.
[11] H. Parving,et al. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] P. Whelton,et al. Trends in pharmacologic management of hypertension in the United States. , 1995, Archives of internal medicine.
[13] M. Kornitzer,et al. Ankle/Arm Pressure Index in Asymptomatic Middle-Aged Males: An Independent Predictor of Ten-Year Coronary Heart Disease Mortality , 1995, Angiology.
[14] M. Laakso,et al. NIDDM and Its Metabolic Control Predict Coronary Heart Disease in Elderly Subjects , 1994, Diabetes.
[15] R. Schrier,et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. , 1993, The Online journal of current clinical trials.
[16] D. Waters,et al. Interventions that beneficially influence the evolution of coronary atherosclerosis. The case for calcium channel blockers. , 1992, Circulation.
[17] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[18] S. Yusuf,et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.
[19] J. Huttunen,et al. Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study , 1992, Diabetes Care.
[20] R. Klein,et al. Cause-specific mortality in a population-based study of diabetes. , 1991, American journal of public health.
[21] L. Kuller,et al. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. , 1991, Atherosclerosis.
[22] J. Deckers,et al. Retardation of angiographic progression of coronary artery disease by nifedipine , 1990, The Lancet.
[23] R. Hamman,et al. Diagnostic methods for peripheral arterial disease in the San Luis Valley Diabetes Study. , 1990, Journal of clinical epidemiology.
[24] D. B. Weinstein,et al. Protective action of calcium channel antagonists in atherogenesis and experimental vascular injury. , 1989, American journal of hypertension.
[25] C. Mogensen. Microalbuminuria and diabetic renal disease , 1989 .
[26] R. Kahn. Report and Recommendations of the San Antonio Conference on Diabetic Neuropathy , 1988, Diabetes Care.
[27] H. Janka,et al. Systolic Blood Pressure as a Predictor for Cardiovascular Disease in Diabetes: A 5‐Year Longitudinal Study , 1985, Hypertension.
[28] Diabetes mellitus. Report of a WHO Study Group. , 1985, World Health Organization technical report series.
[29] N Reichek,et al. Echocardiographic Determination of Left Ventricular Mass in Man: Anatomic Validation of the Method , 1977, Circulation.
[30] H. Tyroler,et al. Angina pectoris and the Rose questionnaire. , 1971, Archives of internal medicine.